April 24, 2017 / 12:14 PM / 3 months ago

BRIEF-Durect presents data from a Phase 1B study of DUR-928 in nonalcoholic steatohepatitis (NASH)

1 Min Read

April 24 (Reuters) - Durect Corp

* Durect announces presentation of data from a Phase 1B study of DUR-928 in nonalcoholic steatohepatitis (NASH)

* DUR-928 was well tolerated in study

* Additional studies, including larger controlled trials, will be required to confirm findings

* Durect - reduction of biomarkers, results from animal, cell culture studies suggest potential therapeutic activity of DUR-928 in patients with liver disease Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below